Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ).
Shandong Boan Biotechnology Co., Ltd. announced that its novel CD228-directed antibody drug conjugate, BA1302, has been granted Orphan Drug Designations by the U.S. FDA for treating squamous non-small-cell lung cancer and pancreatic cancer. This designation is expected to support the drug’s research, registration, and commercialization in the U.S., potentially lowering development costs and accelerating its market launch. The designation highlights the urgent need for effective treatments for these cancers, which have poor prognoses and limited treatment options. BA1302’s specificity to tumor cells and reduced off-target toxicity make it a promising candidate for addressing unmet therapeutic needs.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative drug products, particularly antibody drug conjugates (ADCs). The company is engaged in clinical trials for its products, including BA1302 and BA1301, and is involved in preclinical research for other innovative drugs.
YTD Price Performance: -7.40%
Average Trading Volume: 230,174
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.63B
For detailed information about 6955 stock, go to TipRanks’ Stock Analysis page.